WallStSmart

Merck & Company Inc (MRK)vsTango Therapeutics Inc (TNGX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 115299% more annual revenue ($65.77B vs $56.99M). MRK leads profitability with a 13.6% profit margin vs -188.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

TNGX

Avoid

20

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$120.79

$39.83 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for TNGX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TNGX1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TNGX4 concerns · Avg: 3.0/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-27.4%2/10

ROE of -27.4% — below average capital efficiency

Revenue GrowthGrowth
-100.0%2/10

Revenue declined 100.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TNGX

The strongest argument for TNGX centers on Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TNGX

The primary concerns for TNGX are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while TNGX is a turnaround play — different risk/reward profiles.

TNGX carries more volatility with a beta of 1.19 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Tango Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.

Want to dig deeper into these stocks?